All In Biotech

Drug Trial Radar · NCT00630747

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy

Last checked: Nov 20, 2026Latest source record: Jun 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

94

Actual

Start

Sep 13, 2004

Primary completion

Jan 31, 2008

Study completion Jan 31, 2008

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Mar 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study TKT024EXT was a long-term, single-arm, open-label extension of Study TKT024, a one year Phase 2/Phase 3 registration study. The primary objective of this extension study was to collect long-term safety and clinical outcome data in Mucopolysaccharidosis II (MPS II), also known as Hunter Syndrome, from the Phase 2/Phase 3 Study TKT024. All patients enrolling into this study received weekly active treatment with idursulfase, the primary dosing regimen investigated in Study TKT024. Hunter Syndrome is an X-linked recessive lysosomal storage disease caused by a deficiency of iduronate-2-sulfatase, an enzyme required to catabolize glycosaminoglycans (GAGS) in cells. As a result, GAGs accumulate in the lysosomes leading to cellular engorgement, organomegaly, tissue destruction, and organ system dysfunction. Hunter Syndrome is a rare disease with an estimated incidence of 1 in 162,000 live births.

Conditions

  • Hunter Syndrome
  • Mucopolysaccharidosis II (MPS II)

Interventions

  • IdursulfaseBiological

    Solution for intravenous infusion, 0.5 mg/kg once-weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Percent Predicted Forced Vital Capacity (FVC) at Week 105Time frame: Baseline and at Week 105
  2. Change From Baseline in Mean Distance Walked in the 6-minute Walk Test (6MWT) at Week 105Time frame: Baseline and at Week 105

Locations

52 sites in 10 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital

    Phoenix, Arizona

  • Pediatric Clinical Research Center, Children's Hospital Oakland

    Oakland, California

  • The Children's Hospital

    Denver, Colorado

  • Harbin Clinic

    Rome, Georgia

  • Mid-Illinois Hematology and Oncology Associates

    Normal, Illinois

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Children's Hospital Boston

    Boston, Massachusetts

  • Saint Louis University Cardinal Glennon Children's Hospital

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Upstate Medical University, State University of New York (SUNY)

    Syracuse, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Baylor College of Medicine Texas Children's Hospital

    Houston, Texas

  • University of Utah Hospital

    Salt Lake City, Utah

  • Franciscan Skemp Healthcare

    La Crosse, Wisconsin

  • Fundacao Universidade de Ciencias da Saude de Alagoas Governador Lamenha Filho / UNCISAL

    Maceió, Alagoas, Brazil

  • Clinica Casa de Saude Sao Joao

    Barreiras, Estado de Bahia, Brazil

  • c-HUPES/UFBA

    Salvador, Estado de Bahia, Brazil

  • Hospital Universitario da Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul

    Campo Grande, Mato Grosso do Sul, Brazil

  • Instituto de Puericultura e Pediatria Martagao Gesteira / Hospital Pediatrico

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Hospital de Clinicas de Porto Alegre, Servico de Genetica Medica

    Porto Alegre, Rio Grande do Sul, Brazil

  • UNIFESP Instituto de Oncologia Pediatrica

    São Paulo, São Paulo, Brazil

  • Instituto da Crianca / Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo

    São Paulo, São Paulo, Brazil

  • The Hospital for Sick Children Research Institute

    Toronto, Ontario, Canada

  • University of Montreal / Hopital Ste-Justine

    Montreal, Quebec, Canada

  • Hopital Edouard Herriot

    Lyon, France

  • Hopital de Hautepierre

    Strasbourg, France

  • Hospital Ducuing

    Toulouse, France

  • Universitatsklinikum Aachen Kinderklinik

    Aachen, Germany

  • Universitatsklinik Dusseldorf Kinderklinik

    Düsseldorf, Germany

  • Justus-Liebig Universitat

    Giessen, Germany

  • Universitatsklinikum Gottingen

    Göttingen, Germany

  • Universitatsklinikum Hamburg Eppendorf

    Hamburg, Germany

  • Children's University Hospital Mainz AG

    Mainz, Germany

  • Universita Milano Bicocca / Ospedale S. Gerardo

    Milan, Italy

  • Universita degli Studi di Napoli Federico II

    Naples, Italy

  • Universita di Padova

    Padova, Italy

  • Ospedale S. S. Annunziata

    Savigliano, Italy

  • Spitalul Clinic de Copii

    Cluj-Napoca, Cluj, Romania

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.